Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648672 · ClinicalTrials.gov registry record · Phase 1
BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects
A Phase 1 study of Alzheimers Disease, sponsored by Tetra Discovery Partners.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT02648672: Completed Phase 1 study of Alzheimers Disease, sponsored by Tetra Discovery Partners.
NCT02648672 is a Phase 1 study of Alzheimers Disease that has completed, run by Tetra Discovery Partners. The registered enrollment target is 32 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02648672, a Phase 1 study of Alzheimers Disease, has completed, sponsored by Tetra Discovery Partners.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized double-blind (investigator and subject blinded), placebo controlled ascending single dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy male and female subjects. Each subject will be randomized to receive either a single dose of BPN14770 or placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BPN14770
Study Locations (1)
Michigan
- Jasper Clinic - Kalamazoo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02648672
The ClinicalTrials.gov registry entry for NCT02648672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The listed sponsor is Tetra Discovery Partners, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02648672 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02648672 about?
NCT02648672 is a clinical study titled "BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects". This is a randomized double-blind (investigator and subject blinded), placebo controlled ascending single dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy male and female subjects. Each subject will be randomized to receive either a single dose of B...
What is the current status of trial NCT02648672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-12. Estimated completion is 2016-07.
What conditions does trial NCT02648672 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT02648672?
The interventions under investigation include: Placebo (DRUG), BPN14770 (DRUG).
Who is sponsoring clinical trial NCT02648672?
This trial is sponsored by Tetra Discovery Partners, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02648672 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.